Pricing Log in Create free account
Friday 6 November 2026 Export IMVT’s income statement to Excel — free account

Immunovant, Inc.

IMVT Healthcare Biotechnology

EPS
−5.63%
Free cash flow
−5.96%

Quarter to June 2026, against a year earlier

30.53 2.14 +7.54%
Market cap
$5.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Immunovant, Inc. 10-Q filed Aug 6, 2026

Fiscal Q1 2027 · Period ended Jun 30, 2026 · Filed · accepted 7:29 AM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 11, 2025: 13 added · 13 removed · 37 modified; 6 with only figures updated; 1 moved without change